Lab Automation Networks Proliferating
Although it may still seem radically innovative in the context of many clinical laboratories, automated production in the manufacturing sector had been the norm for many years. In automobile assembly, for example, automated lines fabricate sub-assemblies and entire vehicles with only occasional human oversight. The result has been vastly improved products, far fewer defects, and significant p...
GTC Biotherapeutics to Webcast Corporate Presentation at the C.E.
Unterberg, Towbin Emerging Growth Life Opportunities Conference
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTCBiotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today thatGeoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled topresent on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E.Unterberg, Towbin Emerging Growth
Life Opportunities Conference.The conference is being held at the Mandarin Oriental Hotel, NewYork, New York from July...
Suven Life Sciences Presenting Pre-clinical data of their
NCE’s SUVN-502 and SUVN-507at International Brain Research
Organization (IBRO) 2007 World Congress of Neuroscience
HYDERABAD, India, July 5th, 2007 – Several datapresentations from Suven’s portfolio of investigationalneuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 WorldCongress of Neuroscience to be held at Melbourne, Australia duringJuly 12-17, 2007. Scientists from Suven Discovery Research will be presenting newdata for 4 p...
Advanced Life Sciences Announces Supplemental Efficacy Data from
First Pivotal Phase 3 Pneumonia Clinical Trial
Provides Update to Timeline for Second Pivotal Phase 3 Trial CL-05 CHICAGO, July 02, 2007 /PRNewswire-FirstCall/ -- Advanced
LifeSciences Holdings, Inc. , today announced the confirmation ofsupplemental efficacy data from Trial CL-06, the first of twopivotal Phase 3 clinical trials designed to assess the safety andeffectiveness of cethromycin, a novel once-a-day antibiotic, forthe treatme...
Advanced Life Sciences to Host Conference Call to Discuss Data From
Cethromycin's First of Two Phase 3 Pneumonia Trials
CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced
LifeSciences Holdings, Inc. , today announced that it will host aconference call and live webcast at 10:00 am (EDT) on Monday, July2, 2007 to discuss data from Trial CL-06, the first of two pivotalPhase 3 clinical trials designed to assess the safety andeffectiveness of cethromycin, a novel once-a-day antibiotic, forthe treatment...
HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove
Superior at International Conference
BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - Hepa
Life Technologies, Inc.(OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that newdata presented at an international influenza research conferencedemonstrates that Hepa
Life's patented PBS-1 cell line outperformscurrent cell technologies at replicating human influenza virusinside its cells. The most important step towards the production ofa cel...
BioLife Solutions Presents Data on CryoStor at International
Society for Cellular Therapy Annual Meeting
Independent Study Indicates 20-50% Improvement in Post-PreservationFunctional Recovery of Peripheral Blood Stem Cells for CancerTherapy BOTHELL, Wash., June 25, 2007 /PRNewswire-FirstCall/ -- Bio
LifeSolutions Inc. , a leading developer and marketer of proprietaryhypothermic storage and cryopreservation media products for cells,tissues, and organs, today presented data from an independent...
Answerthink and LORENZ Life Sciences Group Announce Strategic
Alliance for the SAP Life Science Industry
MIAMI--(BUSINESS WIRE)--Jun 21, 2007 - Answerthink, Inc. (NASDAQ:ANSR) announced today that it has formed a strategic alliance withLORENZ
Life Sciences Group for the distribution of LORENZ solutionsin North America. Answerthink and LORENZ
Life Sciences Group willserve midsize companies by integrating best practice submissionsmanagement solutions into Answerthink's
Life Science solutionsbase...
LifeCycle Pharma Announces Positive Phase I Clinical Results for
its Transplantation Product Candidate, LCP-Tacro
Heads into US Phase II Clinical Trials for Organ Transplantation HORSHOLM, Denmark, May 31, 2007 /PRNewswire-FirstCall/ --
LifeCycle Pharma announces positive Phase I clinical results forits transplantation product candidate, LCP-Tacro - Heads into USPhase II clinical trials for organ transplantation. Today
LifeCycle Pharma A/S (OMX:LCP) announces positive resultsfrom its Phase I cli...
HepaLife Announces Scientific Presentation of PBS-1 Cell Line at
International Influenza Meeting
BOSTON--(BUSINESS WIRE)--May 29, 2007 - Hepa
Life Technologies, Inc.(OTCBB:HPLF) (FWB:HL1) (WKN:500625) is pleased to announce ascientific presentation of its cell based PBS-1 technology forpotential influenza vaccine production at the "Options for theControl of Influenza VI Conference," to be held June 17-23, 2007,in Toronto, Canada. Entitled "High titer growth of human and avian influenz...
Separate Sets of Research Show Treatment Improved Quality of Life
in as Early as Three Weeks; Patient Adherence to Medication is
Multifactorial
WASHINGTON, May 22, 2007 /PRNewswire/ -- Results from analyseslooking at factors contributing to successful treatment ofulcerative colitis (UC), were presented at Digestive Disease Week(DDW) this week. Both of these studies were funded by Procter &Gamble (P&G) Pharmaceuticals, Inc. Findings from one studyoffer new information on improvement of quality of
life for UCpatients t...
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many
Aspects of Daily Life
UC's Overall Psychological Toll Is Greater Than for Asthma,Rheumatoid Arthritis and Migraines WAYNE, Pa., May 17, 2007 /PRNewswire/ -- Nearly three out offour ulcerative colitis (UC) sufferers (73 percent) responding to anew nationwide survey say not feeling well has become a normal partof
life. Furthermore, they describe UC as disruptive when it comesto their relationship with a spouse (...
Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase
I/IIa 6-Month Results at 75th Annual Meeting of the American
Association of Neurological Surgeons
Company Announces Extension of Phase I/IIa Trial to 9 mg DosageLevel HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ --Boston
Life Sciences announced today that clinical data on its leadnerve repair therapy, Cethrin(R), were presented in the Neurotraumaand Critical Care Scientific Session at the 75th Annual Meeting ofthe American Association of Neurological Surgeons (AANS) inWash...
Major Discovery Raises Prospect of Better Patient Care By Improving
Platelet Life Span
MELBOURNE, Australia, March 23, 2007 /PRNewswire/ -- Scientistsat WEHI have made a discovery with potentially profoundimplications for the care of patients, especially those undergoingcancer chemotherapy. The research team led by Drs Benjamin Kile and David Huang hasdiscovered that platelet
life span is controlled by two keymolecules. The discovery raises the prospect of developing...